Sanofi : Phase III positive for Onpattro in ATTR with cardiomyopathy
>Encouraging top-line data for a priority review as of H2 - Sanofi's share price gained more than 3% yesterday following the announcement of the positive top-line results of its partner Alnylam (+37%). The phase III study (HELIOS-B) evaluating vutrisiran (Amvuttra) in the treatment of amyloid transthyretin cardiomyopathy (ATTR-CM), a rare life-threatening systemic disease. The study thus achieved its main endpoint of reducing the composite score of all causes of ...Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.